206265-94-3

Usage

Explanation

This is the chemical name of the compound, which is a long and complex name that describes its structure and composition.

Explanation

The compound is primarily used in the pharmaceutical industry, meaning it plays a role in the development and production of medications.

Explanation

The compound is commonly employed as a reagent, which means it is used in chemical reactions to help create new compounds or modify existing ones. This is particularly important in the development of new drugs.

Explanation

The compound is known for its ability to alter the properties of other molecules, making it a valuable tool for researchers. This can help in creating new medications with improved or desired characteristics.

Explanation

The compound's unique structure and properties make it an essential part of many pharmaceutical products and research studies. This is likely due to its ability to modify other molecules and contribute to the development of new medications.

Industry

Pharmaceutical

Use

Reagent in organic synthesis and drug development

Property modification

Ability to modify the properties of certain molecules

Unique structure and properties

Important component in the creation of various pharmaceutical products and research studies

Upstream product

• 139115-92-7 tert-butyl 2-(2-(2-hydroxyethoxy)ethoxy)ethylcarbamate 
• 98-59-9 p-toluenesulfonyl chloride 
• 112-27-6 2,2'-[1,2-ethanediylbis(oxy)]bisethanol 
• 57641-67-5 2-(2′-(2″-bromoethoxy)ethoxy)ethanol 
• 6338-55-2 2-(2-(2-aminoethoxy)ethoxy)ethan-1-ol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 178685-33-1 8-azido-3,6-dioxaoctyl tosylate 
• 19249-03-7 triethylene glycol di-(p-toluenesulfonate) 

Downstream Products

• 1114988-38-3 C₄₁H₇₁N₃O₁₇ 
• 1400565-56-1 2-(2-(2-(4-(2-(2-(3,4-bis(2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yloxy)phenethylamino)-2-oxoacetamido)ethyl)-2-(2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yloxy)phenoxy)ethoxy)ethoxy)ethyl tert-butylcarbamate 
• 1400565-48-1 N,N'-(2,2'-(2,2'-(2,2'-(4-(2-(4-azido-2,3,5,6-tetrafluorobenzamido)ethyl)-1,2-phenylene)bis(oxy)bis(ethane-2,1-diyl))bis(oxy)bis(ethane-2,1-diyl))bis(oxy)bis(ethane-2,1-diyl))bis(4-azido-2,3,5,6-tetrafluorobenzamide) 
• 1400565-50-5 N,N'-(2,2'-(2,2'-(2,2'-(4-(2-(4-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzamido)ethyl)-1,2-phenylene)bis(oxy)bis(ethane-2,1-diyl))bis(oxy)bis(ethane-2,1-diyl))bis(oxy)bis(ethane-2,1-diyl))bis(4-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzamide) 
• 1400565-54-9 C₃₀H₅₃N₃O₁₀ 
• 1400565-42-5 2-(2-(2-(4-(2-(tert-butoxycarbonylamino)ethyl)-2-(2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yloxy)phenoxy)ethoxy)ethoxy)ethyl tert-butylcarbamate 
• 1400565-52-7 2-(2-(2-(4-(2-(benzyloxycarbonylamino)ethyl)-2-(2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yloxy)phenoxy)ethoxy)ethoxy)ethyl tert-butylcarbamate 

Relevant academic research and scientific papers

TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE

This disclosure relates to bivalent compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the bivalent compounds, and to methods of use the bivalent compounds for the treatment of certain disease in a subject in need thereof. The disclosure also relates to methods for identifying such bivalent compounds.

Small molecule compound based on EZH2 protein degradation, and application thereof

The invention discloses a series of small molecule compounds capable of selectively degrading EZH2 protein, and application thereof. The compounds can be prepared into proper pharmaceutical dosage forms for EZH2-mediated related tumor treatment.

Heterocyclic compound and application thereof

The invention discloses a heterocyclic compound and application thereof. The invention provides a heterocyclic compound as shown in a formula I, or pharmaceutically acceptable salt thereof. The heterocyclic compound can be used for degrading ALK, c-Met and ROS proteins.

Neem PROTAC compound with STAT3 degradation activity and preparation method and application thereof

A NEEM PROTAC compound with STAT3 degradation activity, the structure of which is generally formula (I): Y is a specific protein ligand in the E3 ubiquitin ligase complex, a Cereblon protein ligand or A VHL protein ligand; X is a linking group between nee

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE

Bivalent compounds, compositions comprising one or more of the bivalent compounds, and methods of use the bivalent compounds for the treatment of certain disease in a subject in need thereof are provided. Methods for identifying such bivalent compounds are provided, either.

Compound for targeted degradation of ALK, c-Met and ROS1 proteins, and preparation method thereof

The invention provides a novel compound for targeted degradation of ALK, c-Met and ROS1 proteins, wherein the compound is represented by a formula A, is formed by linking an ubiquitin ligase E3 recognition ligand and an ALK, c-Met and ROS1 protein inhibitor compound through a linking arm, and can selectively induce degradation of ALK, c-Met and ROS1 proteins and mutant proteins of the ALK, c-Met and ROS1 proteins. According to the invention, a bifunctional small molecule is obtained; and in-vitro anti-tumor activity data of the compound show that the compound has high-efficiency anti-tumor activity on conventional tumor cells, has strong inhibition activity on mutant cell strains (BaF3/EML4-ALKG1202R, BaF3/EML4-ALKL1196M and BaF3-TEL-ALK-C1156Y) causing the drug resistance, provides a effective antitumor drug for clinical application, has great application value, brings good news for tumor treatment, especially for some drug-resistant patients, and has important social benefits.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

PROTEIN DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the targeted degradation of proteins, and the treatment of target protein-mediated disorders.

SUBSTITUTED 1-METHYL-1,2,3,4-TETRAHYDROISOQUINOLINE MOLECULES AS PCSK9 ALLOSTERIC BINDERS

The present invention relates to PCSK9 allosteric binding compounds of Formula I: (Formula (I)) and pharmaceutically acceptable salts thereof, wherein X1, X2, Y, R1, R2, RA, RB and n are as defined herein. The present invention also relates to compositions which comprise an allosteric binding compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates, inter alia, to methods for inducing PCSK9 protein degradation in a subject, and methods for treating atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions, comprising administering to a subject an effective amount of a compound or a pharmaceutically acceptable salt of the invention. The invention also provides a means for the in vitro labeling, detection and/or quantification of PCSK9 in biological samples.